Valneva is developing a Covid-19 vaccine named VLA2001. Its Scottish unit has received a $27 million grant from the Scottish government to fund R&D of manufacturing for VLA2001. The reported funding is described as a grant to support manufacturing research and development. The article does not provide timelines, production-capacity details, or operating metrics such as revenue or users. No other financings or investor participation are mentioned in the provided text. The item appears in a roundup and the fuller article is behind a sign-up prompt, limiting additional publicly available details. Valneva SE commercializes travel vaccines IXIARO/JESPECT (Japanese encephalitis) and DUKORAL (cholera/ETEC) and advances multiple vaccine candidates, including programs for Lyme disease and chikungunya. The company has operations in Austria, Sweden, the United Kingdom, France, Canada and the U.S. and employs close to 500 people. Valneva completed Phase 2 patient recruitment for its Lyme program at the end of September and expects to report primary endpoint data mid‑2020. Management confirmed a mid‑term intention to list on Nasdaq, subject to shareholder approval, to co‑fund late‑stage development of the Lyme program. The company announced a debt financing to support advancement of its pipeline and to repay existing debt. Guggenheim Securities served as financial advisor and Dechert LLP as legal advisor in the transaction. Valneva develops and commercializes vaccines for infectious diseases with major unmet needs. Its commercial portfolio includes IXIARO/JESPECT for the prevention of Japanese encephalitis and DUKORAL for the prevention of cholera and, in some countries, ETEC-related diarrhea. The company has multiple vaccines in development, including unique candidates against Lyme disease and chikungunya. Valneva operates in Austria, Sweden, the United Kingdom, France, Canada and the US and has approximately 480 employees. The company announced a drawdown of €10 million from an existing European Investment Bank loan to support R&D and advance its clinical development-stage assets. Including this tranche, Valneva has drawn down €20 million of the €25 million facility and does not intend to draw the remaining €5 million. Valneva is a fully integrated, commercial-stage biotechnology company focused on developing and commercializing vaccines. The company markets two traveler vaccines: IXIARO®/JESPECT® for Japanese encephalitis and DUKORAL® for cholera and some ETEC-related diarrhea. Its proprietary pipeline includes candidates against Clostridium difficile and Lyme Borreliosis, and it leverages technology platforms such as the EB66® cell line and the IC31® adjuvant. Valneva pursues financial returns through focused R&D investments and growing contributions from its commercial products, aiming for financial self-sustainability. The company is listed on Euronext-Paris and the Vienna stock exchange and operates in France, Austria, Great Britain, Sweden, Canada and the US with over 400 employees. Valneva is a fully integrated vaccine company focused on development, manufacture and commercialization of preventive vaccines. Its commercial portfolio includes two traveler vaccines: IXIARO/JESPECT for Japanese encephalitis and DUKORAL for cholera (and ETEC-related diarrhea in some countries). The company advances proprietary candidates including programs against Clostridium difficile and Lyme Borreliosis and leverages platforms such as the EB66 production cell line and the IC31 adjuvant. Valneva planned to enter its Lyme Borreliosis vaccine into Phase I in 2016 and is conducting preclinical R&D on a Zika vaccine candidate. Financially it is moving toward EBITDA break-even, intends to fund a substantial part of R&D from commercial product cash flows, and targets R&D spending of 15–20% of revenues. The company reports approximately 400 employees and is listed on Euronext Paris and the Vienna stock exchange.

Total raised

$172M

Funding rounds

6

Latest round

Grant

Latest activity

Feb 2022